home / stock / alxo / alxo news

ALXO News and Press, ALX Oncology Holdings Inc. From 12/07/20

Stock Information
Company Name: ALX Oncology Holdings Inc.
Stock Symbol: ALXO
Market: NASDAQ
Website: alxoncology.com
Menu
ALXO ALXO Quote ALXO Short ALXO News ALXO Articles ALXO Message Board
Get ALXO Alerts

News, Short Squeeze, Breakout and More Instantly...
ALXO - ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma

-- ORR of 70 .0 % Observed in Patients with NHL Treated with Higher Doses of ALX148 with Median Duration of Response Not Yet Reached -- Significant Improvement in Clinical Response Demonstrated with Increased ALX148 Exposure BURL...
ALXO - ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies

-- Due to the registration potential of two planned Phase 2 head and neck cancer studies , FDA has requested completion of a standard ongoing non-clinical safety study -- Initiation of planned Phase 2 studies is allowed ...

ALXO - ALX Oncology Announces December 2020 Virtual Investor Conference Participation

BURLINGAME, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President an...

ALXO - ALX Oncology Holdings (ALXO) Presents New ALX148 Data from the Phase 1b Gastric/GEJ Expansion Cohort in ASPEN-01 - Slideshow

The following slide deck was published by ALX Oncology Holdings Inc. in conjunction with this event. For further details see: ALX Oncology Holdings (ALXO) Presents New ALX148 Data from the Phase 1b Gastric/GEJ Expansion Cohort in ASPEN-01 - Slideshow

ALXO - ALX Oncology reports Q3 results

ALX Oncology (ALXO): Q3 GAAP net loss of $10.8MNon-GAAP net loss of $9.1MCash and cash equivalents of $259.5MPress Release For further details see: ALX Oncology reports Q3 results

ALXO - ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights

BURLINGAME, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quarter ended ...

ALXO - ALX Oncology (ALXO) Investor Presentation - Slideshow

The following slide deck was published by ALX Oncology Holdings Inc. in conjunction with this event. For further details see: ALX Oncology (ALXO) Investor Presentation - Slideshow

ALXO - ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors

-- ORR of 64 % Observed in Patients with > 2L HER2 Positive Gastric/Gastroesophageal Junction Cancer -- ORR of 75% and One Complete Response Observed in Patients with 1L Head and Neck Cancer -- ALX Onco...

ALXO - ALX Oncology to Present ALX148 Clinical Data at the 62nd American Society of Hematology (ASH) Annual Meeting

BURLINGAME, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that both ALX148 clinical and preclinical re...

ALXO - ALX Oncology Announces November 2020 Virtual Investor Conference Participation

BURLINGAME, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President an...
Previous 10 Next 10